paclitaxelloaded dqasomes uj day after tumor implantation fig tumor growth inhibition study in nude mice implanted with human colon cancer cells the mean tumor volume from each group desogen patient assistance program was blotted against the number of days each group involved animals for clarity, error bars were omitted note desogen patient assistance program that after weeks the dose, normalized for paclitaxel, was tripled in all desogen patient assistance program treatment groups empty dqasomes do not show any impact on tumor growth, desogen patient assistance program paclitaxelloaded dqasomes with paclitaxel and dequalinium desogen patient assistance program concentrations identical to controls seem to inhibit the tumor growth by about correspondingly, the average ivermectin rates goats tumor weight in the treatment group, after sacrificing the animals days, later was approximately desogen patient assistance program half of that in all controls desogen patient assistance program although this result seems to suggest that dqasomes might indeed be able to increase the therapeutic potential of desogen patient assistance program paclitaxel, the preliminary character of this desogen patient assistance program first in vivo study has to be emphasized experiments to optimize the treatment protocol are ongoing in the authors laboratory summary since their initial desogen patient assistance program description in , dqasomes and dqasomelike vesicles have been established as the first mitochondriatargeted colloidal delivery system, capable of transporting plasmid dna as well as desogen patient assistance program small drug molecules towards mitochondria within living mammalian cells the further exploration of this unique mitochondriotropic delivery desogen patient assistance program system will introduce new ways for the treatment of cancer and for desogen patient assistance program the therapy of a multitude of mitochondrial diseases acknowledgments i am grateful to prof v p torchilin for many helpful discussions and for his desogen patient assistance program strong and continuous support of my desogen patient assistance program work i also would like to sincerely thank my graduate students, gerard dsouza, shingming cheng, sarathi boddapati and eyad katrangi, whose experimental work has desogen patient assistance program made the writing of this chapter possible i am obliged to the desogen patient assistance program muscular dystrophy association tucson, az, the united mitochondrial disease foundation pittsburgh, pa, mitovec, inc boston, ma and northeastern university boston, ma for the financial support i received from these desogen patient assistance program organizations during the last four years desogen patient assistance program references weissig v, lasch j, erdos g, meyer hw, rowe tc and hughes j dqasomes a novel potential drug and gene delivery system made from dequalinium pharm res � smith desogen patient assistance program ra, porteous cm, gane am and murphy mp delivery of bioactive molecules to mitochondria in vivo proc natl acad sci usa murphy mp and smith ra drug delivery to mitochondria the key to mitochondrial medicine adv drug del rev muratovska a, lightowlers rn, taylor rw, wilce ia and desogen patient assistance program murphy mp targeting large molecules to mitochondria adv drug del rev szewczyk a and wojtczak l mitochondria as a pharmacological target pharmacol rev weissig v mitochondrialtargeted drug and dna desogen patient assistance program delivery crit rev ther drug carr syst weissig v, cheng sm and dsouza g mitochondrial pharmaceutics mitochondrion weissig v targeted drug delivery to mammalian mitochondria in living cells exp opin drug del weissig v, boddapati sv, dsouza ggm and cheng sm targeting desogen patient assistance program of low molecular weight drugs to desogen patient assistance program mammalian mitochondria drug des rev de rosa m, gambacorta a and gliozi a structure, biosynthesis, and physico chemical properties of archaebacterial lipids microbiol rev desogen patient assistance program gambacorta a, gliozi a and desogen patient assistance program de rosa m archaeal lipids and their biotechnological applications world j microbiol desogen patient assistance program biotechnol weissig v, mogel hj, wahab m and lasch j computer simulations of dqasomes proc intl symp control rel bioact mater weissig v, lizano � and torchilin vp a micellar desogen patient assistance program delivery system for dequalinium � a lipophilic cationic drug with anticarcinoma activity j lipos res weissig v, lizano c, ganellin cr and torchilin vp dna binding cationic bolasomes with delocalized charge center a structureactivity relationship study stp pharma sci chrzanowskalightowlers zm, lightowlers rn and turnbull dm gene therapy for mitochondrial dna defects is it possible?